APTX Aptinyx Inc.

Aptinyx Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders.

As of 05/26/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/21/2018
Outstanding shares:  67,715,718
Average volume:  323,791
Market cap:   $36,857,665
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -0.90
PB ratio:   0.48
PS ratio:   7.54
Return on equity:   -103.87%
Net income %:   -1,585.97%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy